This is an an open label clinical trial of sustained-release Melatonin 2mg once daily for 12
weeks in patients with Parkinsons's Disease reporting nocturia, defined as getting up
regularly at night > twice to pass urine. The primary objective of this study is to evaluate
the effects of exogenous melatonin on bother related to nocturia. Secondary objectives are to
evaluate: 1) Mean night time urinary frequency 2)Volume of urine voided at night
3)Incontinence and other lower urinary tract symptoms (LUTS) 3)Quality of sleep 4) Quality of
life 5) Sleep disturbance of partners 6)Safety